Immune Netw.  2020 Feb;20(1):e8. 10.4110/in.2020.20.e8.

Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy

• Kim KH
• Kim CG
• Shin EC

• KMID: 2471048
• DOI: http://doi.org/10.4110/in.2020.20.e8

Abstract

Immune checkpoint blockade targeting PD-1 and PD-L1 has resulted in unprecedented clinical benefit for cancer patients. Anti-PD-1/PD-L1 therapy has become the standard treatment for diverse cancer types as monotherapy or in combination with other anti-cancer therapies, and its indications are expanding. However, many patients do not benefit from anti-PD-1/PD-L1 therapy due to primary and/or acquired resistance, which is a major obstacle to broadening the clinical applicability of anti-PD-1/PD-L1 therapy. In addition, hyperprogressive disease, an acceleration of tumor growth following anti-PD-1/PD-L1 therapy, has been proposed as a new response pattern associated with deleterious prognosis. Anti-PD-1/PD-L1 therapy can also cause a unique pattern of adverse events termed immune-related adverse events, sometimes leading to treatment discontinuation and fatal outcomes. Investigations have been carried out to predict and monitor treatment outcomes using peripheral blood as an alternative to tissue biopsy. This review summarizes recent studies utilizing peripheral blood immune cells to predict various outcomes in cancer patients treated with anti-PD-1/PD-L1 therapy.

Keyword

Blood; Biomarkers; PD-1 receptor; Programmed cell death 1 ligand 1; Prognosis; Adverse drug event

MeSH Terms

Acceleration
Antigens, CD274
Biomarkers*
Biopsy
Drug-Related Side Effects and Adverse Reactions
Fatal Outcome
Humans
Prognosis
Programmed Cell Death 1 Receptor
Antigens, CD274
Biomarkers
Programmed Cell Death 1 Receptor